JP2020526206A5 - - Google Patents

Download PDF

Info

Publication number
JP2020526206A5
JP2020526206A5 JP2020500887A JP2020500887A JP2020526206A5 JP 2020526206 A5 JP2020526206 A5 JP 2020526206A5 JP 2020500887 A JP2020500887 A JP 2020500887A JP 2020500887 A JP2020500887 A JP 2020500887A JP 2020526206 A5 JP2020526206 A5 JP 2020526206A5
Authority
JP
Japan
Prior art keywords
cgamp
sample
test
cells
test compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020500887A
Other languages
English (en)
Japanese (ja)
Other versions
JP7197556B2 (ja
JP2020526206A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/041480 external-priority patent/WO2019014246A1/en
Publication of JP2020526206A publication Critical patent/JP2020526206A/ja
Publication of JP2020526206A5 publication Critical patent/JP2020526206A5/ja
Application granted granted Critical
Publication of JP7197556B2 publication Critical patent/JP7197556B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020500887A 2017-07-10 2018-07-10 がん治療のための染色体不安定性および下流サイトゾルｄｎａシグナル伝達をターゲティングする方法 Active JP7197556B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762530661P 2017-07-10 2017-07-10
US62/530,661 2017-07-10
PCT/US2018/041480 WO2019014246A1 (en) 2017-07-10 2018-07-10 TARGETING CHROMOSOMIC INSTABILITY AND SIGNALING OF CYTOSOLIC DNA IN AVAL FOR THE TREATMENT OF CANCER

Publications (3)

Publication Number Publication Date
JP2020526206A JP2020526206A (ja) 2020-08-31
JP2020526206A5 true JP2020526206A5 (cg-RX-API-DMAC7.html) 2022-08-18
JP7197556B2 JP7197556B2 (ja) 2022-12-27

Family

ID=63036469

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020500887A Active JP7197556B2 (ja) 2017-07-10 2018-07-10 がん治療のための染色体不安定性および下流サイトゾルｄｎａシグナル伝達をターゲティングする方法

Country Status (12)

Country Link
US (2) US11821042B2 (cg-RX-API-DMAC7.html)
EP (1) EP3652349A1 (cg-RX-API-DMAC7.html)
JP (1) JP7197556B2 (cg-RX-API-DMAC7.html)
KR (1) KR20200037796A (cg-RX-API-DMAC7.html)
CN (1) CN111295454A (cg-RX-API-DMAC7.html)
AU (1) AU2018300007A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020000477A2 (cg-RX-API-DMAC7.html)
CA (1) CA3069515A1 (cg-RX-API-DMAC7.html)
IL (1) IL271849A (cg-RX-API-DMAC7.html)
MX (1) MX2020000406A (cg-RX-API-DMAC7.html)
SG (1) SG11202000132WA (cg-RX-API-DMAC7.html)
WO (1) WO2019014246A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201901393VA (en) * 2016-09-02 2019-03-28 Univ Illinois Kif13b-derived peptide and method of inhibiting angiogenesis
US11821042B2 (en) 2017-07-10 2023-11-21 Cornell University Targeting chromosomal instability and downstream cytosolic DNA signaling for cancer treatment
JP7226763B2 (ja) * 2017-08-17 2023-02-21 国立大学法人山口大学 癌幹細胞における薬物耐性の低減剤、癌幹細胞における転移能の抑制剤及び癌の転移性再発リスクを予測する方法
US20230106899A1 (en) * 2019-06-21 2023-04-06 Ifm Due, Inc. Methods of treating cancer
WO2021167478A1 (en) * 2020-02-19 2021-08-26 Ibmc - Instituto De Biologia Molecular E Celular 4-pyrrolidin-1-yl-5-p-tolyl-thieno[2,3-d] pyrimidine for use in the treatment of aging-associated and premature aging diseases through restored chromosomal stability and inhibition of cellular senescence
CN112113821B (zh) * 2020-05-28 2021-09-03 王剑 一种细胞病理学样本的多重染色制片方法
WO2022051420A1 (en) * 2020-09-02 2022-03-10 Memorial Sloan Kettering Cancer Center Methods and compositions for targeting cytosolic dsdna signaling in chromosomally unstable cancers
US20240207248A1 (en) * 2021-04-23 2024-06-27 Baruch S. Blumberg Institute Methods, kits and compositions for reducing chromosomal instability in cancer cells
CN113341154B (zh) * 2021-05-14 2024-11-05 医工瑞思(福建)工程研究中心有限公司 一种检测血栓或凝血相关疾病的生物标志物及其应用
KR20240109977A (ko) 2021-08-26 2024-07-12 볼라스트라 쎄라퓨틱스, 인코포레이티드 Kif18a의 스피로 인돌린 억제제
CN115354078B (zh) * 2022-09-02 2023-07-07 中山大学附属第一医院 骨肉瘤检测标记物及其应用
EP4488389A1 (en) * 2023-07-05 2025-01-08 Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Signature for the prognosis of brain metastasis relapse

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4962091A (en) 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
WO1994007529A1 (en) 1992-09-25 1994-04-14 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6306434B1 (en) 1997-02-12 2001-10-23 Chong Kun Dang Corp. Pharmaceutical composition comprising cyclosporin solid-state microemulsion
GB201121070D0 (en) 2011-12-07 2012-01-18 Isis Innovation composition for delivery of biotherapeutics
JP2016506408A (ja) * 2012-12-19 2016-03-03 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 哺乳動物の環状ジヌクレオチドシグナル伝達経路の薬学的標的化
EP3045917A2 (en) * 2013-09-13 2016-07-20 Sierra Jiménez, Angels Marker for predicting metastasis of breast cancer
SG10201807838SA (en) * 2014-03-11 2018-10-30 Council Queensland Inst Medical Res Determining cancer aggressiveness, prognosis and responsiveness to treatment
CN107106544B (zh) * 2014-09-19 2021-09-24 纪念斯隆-凯特琳癌症中心 用于治疗脑转移瘤的方法
WO2016176222A1 (en) * 2015-04-30 2016-11-03 University Of Washington Cgas in systemic lupus erythematosus (sle)
US11821042B2 (en) 2017-07-10 2023-11-21 Cornell University Targeting chromosomal instability and downstream cytosolic DNA signaling for cancer treatment

Similar Documents

Publication Publication Date Title
Park et al. Yes‐associated protein 1 and transcriptional coactivator with PDZ‐binding motif activate the mammalian target of rapamycin complex 1 pathway by regulating amino acid transporters in hepatocellular carcinoma
Gutierrez et al. Phenothiazines induce PP2A-mediated apoptosis in T cell acute lymphoblastic leukemia
US11058903B2 (en) Methods for identifying and treating cachexia or pre-cachexia using an inhibitor of rage
JP6750069B2 (ja) 癌の分類および使用法
US11447831B2 (en) Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonists
US20190192517A1 (en) Treatment of squamous cell carcinomas with inhibitors of erk
CN103382503B (zh) Egfr基因19号外显子19种缺失突变检测试剂盒及检测方法
EP2407783A1 (en) A method for pharmacologically profiling compounds
US20210130903A1 (en) Targeting chromosomal instability and downstream cytosolic dna signaling for cancer treatment
CN107663533A (zh) 一种肺癌EGFR L858R和19Del的ddPCR检测方法及应用
WO2020046966A1 (en) Treatment of adenocarcinomas with mapk pathway inhibitors
KR20220123064A (ko) Cdk12/13 억제제에 의한 암 치료
KR20180042819A (ko) Hsp90 억제제 내성 세포주 및 이를 이용한 항암제 스크리닝 방법
WO2012112245A1 (en) Modulation of phosphatidylinositol-5-phosphate-4-kinase activity
JP6323979B2 (ja) うつ病マーカー、アッセイ方法、測定方法、うつ病薬のスクリーニング方法及びキット
Zhao et al. BZW1 as an oncogene is associated with patient prognosis and the immune microenvironment in glioma
US20130004424A1 (en) Methods for determining agents targeting mena isoforms and uses thereof for diagnosis and treatment of metastatic tumors
CN109554469A (zh) T细胞急性淋巴性白血病的肿瘤细胞及其分子标志
KR102132222B1 (ko) 항암제 내성 진단 마커로서의 miR-143-3p 및 miR-373-5p, 및 이의 이용
Du et al. A novel break site of EML4‐ALK report and a rare PRKAR1A‐ALK report analyzed by different ALK detection platforms in non‐small cell lung cancer patients
JPWO2012002274A1 (ja) 培養細胞を用いたｓ１ｐリアーゼ阻害剤のスクリーニング方法
WO2012130720A2 (en) PREDICTION OF RESPONSIVENESS TO PIK3/mTOR INHIBITORS
CN105838781A (zh) ddPCR技术监测伊马替尼(格列卫)/尼罗替尼继发耐药的方法
Hao et al. Discovery of anti-tumor small molecule lead compounds targeting the SH3 domain of c-Src protein through virtual screening and biological evaluation
CN115887657A (zh) Jak2/stat3抑制剂单独或联合卡铂在制备乳腺癌治疗药物中的应用